Cytek Biosciences Company Insiders
CTKB Stock | USD 3.69 0.36 10.81% |
Cytek Biosciences employs about 663 people. The company is managed by 14 executives with a total tenure of roughly 1547 years, averaging almost 110.0 years of service per executive, having 47.36 employees per reported executive. Analysis of Cytek Biosciences' management performance can provide insight into the company performance.
Cytek Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0351) % which means that it has lost $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0291) %, meaning that it created substantial loss on money invested by shareholders. Cytek Biosciences' management efficiency ratios could be used to measure how well Cytek Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Cytek Biosciences Workforce Comparison
Cytek Biosciences is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,316. Cytek Biosciences totals roughly 663 in number of employees claiming about 29% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.06) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.36) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.36. Cytek Biosciences Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytek Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytek Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Cytek Biosciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Wenbin Jiang over a week ago Disposition of 14733 shares by Wenbin Jiang of Cytek Biosciences subject to Rule 16b-3 | ||
Imper Vera over a month ago Acquisition by Imper Vera of 23809 shares of Cytek Biosciences at 3.07 subject to Rule 16b-3 | ||
Imper Vera over a month ago Acquisition by Imper Vera of 23809 shares of Cytek Biosciences at 3.07 subject to Rule 16b-3 | ||
Hardison Don M over a month ago Acquisition by Hardison Don M of 15706 shares of Cytek Biosciences subject to Rule 16b-3 | ||
Barnett Valerie over three months ago Acquisition by Barnett Valerie of 10313 shares of Cytek Biosciences subject to Rule 16b-3 | ||
Wenbin Jiang over three months ago Disposition of 4658 shares by Wenbin Jiang of Cytek Biosciences at 4.36 subject to Rule 16b-3 | ||
Holder Michael over three months ago Acquisition by Holder Michael of 2908 shares of Cytek Biosciences subject to Rule 16b-3 | ||
Barnett Valerie over three months ago Acquisition by Barnett Valerie of 3681 shares of Cytek Biosciences subject to Rule 16b-3 |
Cytek Biosciences Notable Stakeholders
A Cytek Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cytek Biosciences often face trade-offs trying to please all of them. Cytek Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cytek Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Wenbin Jiang | CEO President | Profile | |
Todd Garland | Chief Officer | Profile | |
Ming Yan | CTO Director | Profile | |
Melik Ulusu | Senior Chain | Profile | |
Mark Edinger | VP Affairs | Profile | |
Allen Poirson | Senior Development | Profile | |
Connie Wedel | Chief Officer | Profile | |
Chris Williams | Chief Officer | Profile | |
Paul Goodson | Head Relations | Profile | |
William McCombe | Chief Officer | Profile | |
Philippe Busque | Senior Services | Profile | |
Patrik Jeanmonod | Head Analytics | Profile | |
Valerie JD | General Secretary | Profile | |
Paul Williams | Chief Officer | Profile |
About Cytek Biosciences Management Performance
The success or failure of an entity such as Cytek Biosciences often depends on how effective the management is. Cytek Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cytek management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cytek management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California. Cytek Biosciences operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 555 people.
Please note, the presentation of Cytek Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cytek Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Cytek Biosciences' management manipulating its earnings.
Cytek Biosciences Workforce Analysis
Traditionally, organizations such as Cytek Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cytek Biosciences within its industry.Cytek Biosciences Manpower Efficiency
Return on Cytek Biosciences Manpower
Revenue Per Employee | 302.3K | |
Revenue Per Executive | 14.3M | |
Net Loss Per Employee | 9.1K | |
Net Loss Per Executive | 430K | |
Working Capital Per Employee | 495.9K | |
Working Capital Per Executive | 23.5M |
Complementary Tools for Cytek Stock analysis
When running Cytek Biosciences' price analysis, check to measure Cytek Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytek Biosciences is operating at the current time. Most of Cytek Biosciences' value examination focuses on studying past and present price action to predict the probability of Cytek Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytek Biosciences' price. Additionally, you may evaluate how the addition of Cytek Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |